SHANDONG SCIENCE ›› 2018, Vol. 31 ›› Issue (2): 14-20.doi: 10.3976/j.issn.1002-4026.2018.02.003

• Traditional Chinese medicine and natural active products • Previous Articles     Next Articles

Simultaneous determination of wogonin, 4-dicaffeoylquinic acid and chrysin-7-O-Beta-D-glucoronide in rats plasma by UHPLC-MS/MS

LI Cui1,2, LUO Meng-xiong3, NIE Qi-xia2, ZANG Chen2, WANG Guo-hua2, LUO Gan1,2, ZHANG Bao-xian2*   

  1. 1. China Academy of Chinese Medical Science, Beijing 100700, China; 2. Institute of Chinese Materia Medica, China Academy of Chinese Medical Science, Beijing 100700, China; 3. Shandong University of Traditional Chinese Medicine, Jinan 250355, China
  • Received:2017-10-09 Published:2018-04-20 Online:2018-04-20

Abstract:

A rapid ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method was developed for the simultaneous analysis of wogonin, 4dicaffeoylquinic acid and chrysin-7-O-Beta-D-glucoronide in rats plasma. Apiin was selected as the internal standard. The analysis was carried out on an ACQUITY UPLC HSS T3 column (2.1 mm×100 mm, 1.8 μm), with acetonitrile and 0.1% formic acid aqueous solution, gradient elution. The flow rate was 0.2 mL·min-1. Linear responses were obtained for wogonin, 4-dicaffeoylquinic acid and chrysin-7-O-Beta-D-glucoronide ranging from 1 to 1 000 ng·mL-1. The correlation coefficients were better than 0.99. Both recovery rates and matrix effects met the requirement of biological sample analysis. The established UHPLC-MS/MS quantitative analysis method shows high sensitivity, accuracy and satisfying recovery, and can be utilized to determine the pharmacokinetic data of wogonin, 4-dicaffeoylquinic acid and chrysin-7-O-Beta-D-glucoronide in rats plasma.

Key words: rats plasma, 4-dicaffeoylquinic acid, wogonin, chrysin-7-O-Beta-D-glucoronide, UHPLC-MS/MS

CLC Number: 

  • R284.1

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits third parties to freely share (i.e., copy and redistribute the material in any medium or format) and adapt (i.e., remix, transform, or build upon the material) the articles published in this journal, provided that appropriate credit is given, a link to the license is provided, and any changes made are indicated. The material may not be used for commercial purposes. For details of the CC BY-NC 4.0 license, please visit: https://creativecommons.org/licenses/by-nc/4.0